Latest Breaking News On - Opgen investor press contact - Page 3 : comparemela.com

OpGen Reports First Quarter 2023 Financial Results and Provides Business Update

15.05.2023 - Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of approximately 94% compared to the first quarter of 2022Expanded U.S. growth opportunities with the Unyvero UTI De Novo FDA submission and Unyvero .

Curetis gmbOliver schachtEdison groupTechnology platformFoundation for innovative new diagnosticsEuropean investment bankFinancial results of opgen incInternational numberSecurities exchangeGene panelExchange commissionOpgen incOpgen investor press contactAres geneticFisher healthcareInnovative new

Stock Market | FinancialContent Business Page

Stock Market | FinancialContent Business Page
financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.

Oliver schachtCuretis gmbGene panelFinancial results of opgen incExchange commissionInternational numberTechnology platformFoundation for innovative new diagnosticsOpgen investor press contactSecurities exchangeEuropean investment bankEdison groupOpgen incAres geneticFisher healthcareInnovative new diagnostics

Stock Market | FinancialContent Business Page

New yorkUnited statesOliver schachtCuretis gmbOpgen investor press contactExchange commissionHc wainwright coEuropean investment bankTechnology platformSecurities exchangeEdison groupGene panelOpgen incUnyvero platformAres geneticsUnited statesa

OpGen Announces Pricing of $3 5 Million Public Offering

ROCKVILLE, Md., May 01, 2023 (GLOBE NEWSWIRE) OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power.

New yorkUnited statesOliver schachtCuretis gmbOpgen investor press contactSecurities exchangeGene panelOpgen incEdison groupTechnology platformEuropean investment bankExchange commissionHc wainwright coUnyvero platformAres geneticsUnited statesa

OpGen s (OPGN) Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND

OpGen s (OPGN) Curetis Meets All Remaining Key Milestones in R&D Collaboration with FIND
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Curetis gmbJohannes bacherOliver schachtpresidentCecilia ferreyraAlyssa factoredison groupTechnology platformExchange commissionOpgen incSecurities exchangeEuropean investment bankOpgen investor press contactGene panelCuretis gmbhNext generation sequencingSaharan africanChief technology officer